DeviceTalks Boston has ended

DeviceTalks is a conversation among leaders. It’s an evening for an exchange of ideas, insight and contacts among the pioneers of the medical technology industry. Formerly known as the Big 100, this event is held annually in Boston, Orange County and the Twin Cities.

On July 15th, you’re invited to join us for a discussion with some of the area’s most innovative and influential leaders, including Brian Concannon, CEO, Haemonetics; Duane DeSisto, CEO, Insulet; Carmichael Roberts, General Partner North Bridge Venbtures and Founder of  480 Biomedical, Arsenal Medical, Diagnostics for All, MC10 and Dr. Charles Carignan.

DeviceTalks also features four panel discussions on hot issues facing medtech companies. The descriptions of which can be found below. When you register you are automatically allowed entry into any of the panels listed.


Nandini Murthy

ENEM Consulting

Ms. Murthy has over 20 years of work experience in regulatory affairs, clinical and quality assurance functions with multiple device specialties, including cardiology, neurology, radiology and diagnostics. Having served on the Executive team of several companies, she brings a blend of a strategic, solution-oriented mindset along with strong tactical abilities. Much of her experience has been with cutting-edge device and drug-device combination products, with no prior regulatory precedent, and where she has defined the regulatory strategy and plan. Ms. Murthy has a successful track record of on-time execution and FDA approvals. She has authored numerous FDA submissions including original PMAs, original HDE, original IDEs, PMA and IDE Supplements and 510(k)s for novel products.

Ms. Murthy has also designed and executed complex clinical trials including the REMATCH, SPECTACL and BrainGate trials. She has established quality systems to ISO 13485 and FDA Quality System requirements. This complementary work experience helps Ms. Murthy provide comprehensive regulatory support, aligning the engineering and clinical support documentation with overall regulatory strategy.